Rolf A Brekken Selected Research

apricoxib

9/2012	Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
9/2012	Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rolf A Brekken Research Topics

Disease

119	Neoplasms (Cancer) 01/2022 - 10/2002
35	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 10/2004
25	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2003
21	Adenocarcinoma 01/2022 - 03/2005
13	Breast Neoplasms (Breast Cancer) 11/2020 - 09/2006
11	Hypoxia (Hypoxemia) 06/2021 - 09/2003
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2003
8	Lung Neoplasms (Lung Cancer) 01/2017 - 01/2010
5	Carcinogenesis 11/2020 - 08/2010
4	Melanoma (Melanoma, Malignant) 01/2016 - 12/2011
3	Obesity 01/2021 - 12/2017
3	Fibrosis (Cirrhosis) 11/2020 - 08/2009
3	Stomach Neoplasms (Stomach Cancer) 01/2019 - 04/2015
3	Carcinoma (Carcinomatosis) 10/2018 - 09/2012
3	Insulin Resistance 10/2018 - 04/2012
3	Inflammation (Inflammations) 08/2013 - 07/2012
2	Adenocarcinoma of Lung 01/2022 - 10/2013
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2021
2	Pancreatitis 11/2020 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 11/2020 - 12/2016
2	Type 2 Diabetes Mellitus (MODY) 10/2018 - 09/2010
2	Fatty Liver 10/2018 - 12/2017
2	Weight Loss (Weight Reduction) 10/2018 - 10/2007
2	Thrombosis (Thrombus) 01/2016 - 09/2015
2	Endometrial Neoplasms (Endometrial Cancer) 11/2015 - 07/2010
2	Choroidal Neovascularization 11/2015 - 02/2006
2	Necrosis 01/2011 - 09/2003

Drug/Important Bio-Agent (IBA)

46	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 10/2004
25	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2005
15	CollagenIBA 01/2021 - 04/2004
12	PhosphatidylserinesIBA 01/2021 - 05/2006
11	Gemcitabine FDA Link 01/2022 - 05/2006
9	Monoclonal AntibodiesIBA 01/2016 - 09/2003
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 10/2015
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 08/2006
7	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
7	Pharmaceutical PreparationsIBA 12/2021 - 01/2011
7	CytokinesIBA 11/2020 - 06/2008
7	LigandsIBA 01/2017 - 10/2002
7	IntegrinsIBA 10/2016 - 03/2005
6	Biological ProductsIBA 01/2022 - 06/2013
6	Phosphotransferases (Kinase)IBA 01/2019 - 08/2013
6	Cysteine (L-Cysteine)FDA Link 02/2013 - 02/2009
5	Discoidin Domain Receptor 1IBA 01/2020 - 01/2017
5	Bevacizumab (Avastin)FDA Link 03/2016 - 05/2009
5	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 10/2014 - 08/2006
4	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2005
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 07/2015
4	c-Mer Tyrosine KinaseIBA 01/2021 - 11/2018
4	Interleukin-6 (Interleukin 6)IBA 11/2019 - 11/2009
4	Estrogens (Estrogen)FDA Link 01/2019 - 09/2006
4	Indicators and Reagents (Reagents)IBA 08/2017 - 10/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016 - 05/2010
4	EnzymesIBA 11/2013 - 08/2006
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2012 - 02/2003
3	AntibodiesIBA 01/2018 - 08/2013
3	Fibrillar CollagensIBA 11/2017 - 08/2009
3	Phospholipids (Phosphatides)FDA LinkGeneric 08/2017 - 01/2016
3	PeptoidsIBA 05/2016 - 07/2010
3	Therapeutic UsesIBA 01/2016 - 05/2006
3	GTP-Binding Proteins (G-Protein)IBA 12/2015 - 07/2010
3	Small Interfering RNA (siRNA)IBA 01/2011 - 07/2005
2	AngiopoietinsIBA 01/2022 - 02/2014
2	Transcription Factors (Transcription Factor)IBA 06/2021 - 12/2017
2	CeruletideIBA 11/2020 - 01/2019
2	Axl Receptor Tyrosine KinaseIBA 01/2020 - 09/2015
2	Cadherins (E-Cadherin)IBA 11/2019 - 12/2011
2	tyrosine receptor (receptor, tyrosine)IBA 11/2018 - 08/2013
2	bemcentinibIBA 01/2018 - 10/2015
2	Adenosine Triphosphate (ATP)IBA 11/2017 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 08/2017 - 11/2009
2	Fibronectins (Fibronectin)IBA 10/2016 - 10/2016
2	CarbohydratesIBA 05/2016 - 12/2015
2	LipidsIBA 05/2016 - 12/2015
2	Peptides (Polypeptides)IBA 05/2016 - 12/2015
2	Antineoplastic Agents (Antineoplastics)IBA 12/2015 - 09/2012
2	Warfarin (Coumadin)FDA LinkGeneric 10/2015 - 09/2015
2	CXC ChemokinesIBA 04/2015 - 05/2014
2	nintedanibIBA 03/2015 - 06/2013
2	Neutralizing AntibodiesIBA 05/2014 - 11/2007
2	Cell Surface ReceptorsIBA 02/2014 - 08/2010
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 06/2013 - 11/2012
2	apricoxibIBA 09/2012 - 09/2012
2	matrigelIBA 12/2010 - 10/2007
2	Neuropilin-1IBA 08/2010 - 10/2008
2	pleiotrophin (HARP)IBA 05/2010 - 06/2008
2	Immunoglobulin G (IgG)IBA 07/2009 - 01/2007
2	Extracellular Matrix ProteinsIBA 02/2009 - 03/2005
2	Angiogenesis InhibitorsIBA 10/2007 - 10/2007
2	Progestins (Progestagens)IBA 10/2007 - 09/2006
1	dubermatinibIBA 01/2022
1	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2022
1	Interleukin-1 (Interleukin 1)IBA 01/2022
1	Interferon Type IIBA 01/2022

Therapy/Procedure

63	Therapeutics 01/2022 - 10/2003
16	Drug Therapy (Chemotherapy) 01/2022 - 05/2006
4	Immunotherapy 01/2022 - 01/2018
4	Aftercare (After-Treatment) 01/2021 - 10/2004
3	Transplantation 11/2020 - 09/2009
2	Blood Transfusion (Blood Transfusions) 08/2010 - 05/2009